Previous 10 | Next 10 |
Alnylam Therapeutics (ALNY) has submitted an NDA to the FDA for its RNAi candidate vutrisiran for hereditary ATTR ("hATTR") amyloidosis with polyneuropathy.The application is supported by data from the phase 3 HELIOS-A trial, which met its primary and secondary endpoints.At 9 months...
– At 9 Months, Vutrisiran Met Primary and All Secondary Endpoints, with Statistically Significant Improvements in Neuropathy, Quality of Life (QoL), and Gait Speed, Relative to Placebo – – In Majority of Patients, Vutrisiran Showed Reversal of Polyneuropat...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2021 on Thursday, April 29, 2021, before the U.S. financial markets open. Management will provide an ...
ALN-AGT, an investigational RNAi therapeutic targeting angiotensin ("AGT") from Alnylam Pharmaceuticals (ALNY), reduced AGT levels and lowered blood pressure, interim phase 1 results showed.Results, presented at the Joint Meeting of the European Society of Hypertension, showed that patients w...
– Single Doses of Investigational ALN-AGT Achieved Sustained Reductions in Serum Angiotensinogen (AGT) at 12 Weeks Resulting in Reduced Blood Pressure – – Durability of AGT Knockdown Supports the Potential of Once Quarterly or Biannual Dosing – ...
Royalty Pharma (RPRX) has acquired the royalty interest of Oxlumo™ (lumasiran) from Dicerna Pharmaceuticals (DRNA) for a total consideration of up to $240M.As part of the agreement, Dicerna is entitled to receive $180M as an upfront cash payment in addition to contingent sale...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 20 th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 1:30 pm ET. A live audio webcast of th...
- ILLUMINATE-A Phase 3 Study Evaluated the Efficacy and Safety of Lumasiran in Adult and Pediatric Patients with Primary Hyperoxaluria Type 1 (PH1) - - Lumasiran Demonstrated a Clinically Significant Reduction in Urinary Oxalate, a Primary Determinant of Progression to Renal F...
Ionis Pharmaceuticals is at a crossroads. The pipeline begins to take form with a recent setback creating a waterfall dive in the share price. Let's examine the case for Ionis to see if the move is justified. For further details see: Ionis Pharmaceuticals: Recent Setback...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 3 rd Annual CNS Day on Thursday, April 1, 2021 at 11:00 am ET. A live audio webcast of the presentation will be ...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...